@decipherbyveracyte

Risks of grade reclassification among patients with Gleason grade group 1 prostate cancer and PI-RADS 5 findings on prostate MRI

Prognostic Implications of Very High Decipher Scores in Prostate Cancer: Towards a Refined Genomic Risk Classification - PubMed

Determining Optimal Patient Selection for High-intensity Focused Ultrasound for Prostate Cancer - PubMed

Decipher Test Report Overview

Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial - PubMed

Decipher Test Report Overview

In Conversation - Dr. Arnold Patient Voices Video - Prostate Cancer Foundation & Dr. Eric Kim

ASCO 2025: First Survival Outcomes and Biomarker Results of SURE-01: Neoadjuvant Sacituzumab Govitecan Monotherapy, Followed by Radical Cystectomy, in Patients with Muscle-Invasive Urothelial Bladder Cancer

ASCO 2025: Transcriptome Classification of PTEN Inactivation to Predict Survival Benefit from Docetaxel at Start of Androgen Deprivation Therapy (ADT) for Metastatic Prostate Cancer (PC): An Ancillary Study of the STAMPEDE Trials

In Conversation - Dr. Arnold Bullock & Dr. Eric Kim

Patients - Informed Bladder Cancer Care | Decipher® Bladder

Bringing Clarity to Complexity: How Genomic Advances Can Help Guide the Bladder Cancer Journey

IP05-36 Decipher GRID & PSMA-PET to Predict Extra-Prostatic Extension (EPE): Using Glycolysis Expression to Predict EPE

Patients - Personalized Cancer Care | Decipher® Prostate

MP10-10 Molecular Features of Grade Group 2 Prostate Cancer after Radical Prostatectomy

PD12-06 Gene Signatures of Immune Infiltration Portend differential response to sequential intravesical Gemcitabine and docetaxel VS Bacillus Calmette-Guerin in high-risk non-muscle-invasive bladder cancer

Decipher Prostate Genomic Test - Provider Video

AUA 2025 Abstracts

A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer.

Prostate Cancer Risk Factors

Grade and volume progression and its association with the Decipher genomic classifier using patients enrolled in a prospective active surveillance protocol.

ASTRO 2024: A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African American and Non-African American Men with Prostate Cancer (VANDAAM STUDY)

Decipher score as a predictor of response to treatment intensification in the NRG Oncology-RTOG 0534 (SPPORT) phase III randomized post-prostatectomy salvage radiotherapy trial.

Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.

American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)

Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard

ASTRO 2024: A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African American and Non-African American Men with Prostate Cancer (VANDAAM STUDY)

ESMO 2024: Decipher® mRNA Score for Prediction of Survival Benefit from Docetaxel at Start of Androgen Deprivation Therapy for Advanced Prostate Cancer: An Ancillary Study of the STAMPEDE Docetaxel Trials

Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial

Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting

Use of Decipher Prostate Biopsy Test in Patients with Favorable-risk Disease Undergoing Conservative Management or Radical Prostatectomy in the Surveillance, Epidemiology, and End Results Registry

Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study | JCO Precision Oncology

Key Statistics for Prostate Cancer

Use of Decipher Prostate Biopsy Test in Patients with Favorable-risk Disease Undergoing Conservative Management or Radical Prostatectomy in the Surveillance, Epidemiology, and End Results Registry.

MP17-09 Development of a Longitudinal Prostate Cancer Transciptomic & Real-world Clinical Data Linkage | Journal of Urology

Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance - PubMed

AUA 2024: Decipher® Predicts Clinically Significant Upgrading on Final Radical Prostatectomy Pathology

TRANSCRIPTOMIC FEATURES OF CLINICALLY LOCALIZED PROSTATE CANCER ARISING FROM DISTINCT PROSTATE ZONAL REGIONS

Journal of Urology- High Decipher Score Defines The Subgroup Most At Risk of Metastatic Progression

ICYMI: Journal of Urology: Decipher® Predicts Clinically Significant Upgrading

PCF Webinar - Guiding Treatment Choice in Localized Prostate Cancer

Ordering Decipher Prostate for Clinical Trials

Use of Genomics for Active Surveillance

A novel prostate cancer subtyping classifier based on luminal and basal phenotypes

Use of Genomics for Active Surveillance | BackTable Urology Podcast

PCF Monthly Webinar Series- Biomarker Testing

PCF Monthly Webinar Series- Biomarker Testing

How Does Decipher Prostate Work?

Can a Genomic Testing Better Detect Aggressive Prostate Cancer?

What is Decipher Prostate ?

How Genomics Can Help Men Living With Prostate Cancer

Decipher Website